A $3B startup's shares gain on hopes for a cancer blood test
This bloody company is already worth $3.3 billion. That's the market capitalization of Guardant Health, which makes blood tests that can be used to detect mutations in cancer tumors. Shares have doubled from the $19 price set in the company’s October 4 initial public offering, which raised $273 million.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063